Physician profile
Brian M Gross
NPI 1740255348
$1,111.97
in general payments reported to CMS, 2019-2025
27 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $122 · 2021: $22.90 · 2022: $121 · 2023: $133 · 2024: $165 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $459.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $134.58 | 2020-2023 | Breztri |
| Insmed, INC. | $117.01 | 2019-2023 | Arikayce |
| Abiomed | $99.60 | 2024-2025 | Impella |
| Pfizer INC. | $78.07 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.28 | 2022-2023 | Glassia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.88 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $60.42 | 2020-2023 | Dupixent |
| United Therapeutics Corporation | $45.06 | 2019-2024 | Tyvaso |
| Ambu INC. | $43.61 | 2024 | |
| Grifols USA, LLC | $34.62 | 2019-2023 | Prolastin-C Liquid |
| Genzyme Corporation | $33.91 | 2019 | |
| Glaxosmithkline, LLC. | $33.53 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Electromed, INC. | $32.39 | 2019-2024 | Smartvest |
| Mylan Specialty L.P. | $30.42 | 2019 | |
| Shire North American Group INC | $29.34 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $24.81 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $22.39 | 2019 | |
| Abbvie INC. | $19.91 | 2023 | |
| Philips North America LLC | $19.83 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.33 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $16.67 | 2019 | |
| Janssen Biotech, INC. | $16.64 | 2019 | |
| Olympus America INC. | $16.18 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.26 | 2025 | |
| Astellas Pharma US INC | $13.65 | 2019 | |
| Genentech USA, INC. | $11.58 | 2019 | |
| Veran Medical Technologies, INC. | $10.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.